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ABSTRACT
Asthma continues to be one of the major global health problems with the
current therapies being effective yet inadequate in controlling the disease. Asthma
is commonly associated with airway hyperresponsiveness (AHR) involving
hypercontraction of airway smooth muscle cells (ASMCs).

Despite extensive

research, the molecular mechanisms of AHR are poorly understood, thus preventing
development of specific and effective therapies in the treatment of asthma. The
overarching goal of the research presented in this thesis is to elucidate the
mechanisms underlying AHR in asthma. This will not only help us gain a better
insight into the pathophysiology of asthma, but may further lead to the discovery of
novel and improved therapeutic agents.

Our research specifically focuses on

investigating the role played by Kv7 voltage-activated potassium channels in the
pathophysiology of AHR, and evaluating the significance of Kv7 channel regulation
in the treatment of asthma.
Kv7 channel expression in various excitable cells and their functional role in
maintaining the cell membrane in a hyperpolarized state have been studied in great
detail. However, their expression and function in ASMCs was largely unknown.
Through the research presented in this thesis, we provide the first evidence for the
expression of multiple Kv7 channel subtypes in guinea pig and human ASMCs using
qRT-PCR studies. Our further investigation of expression of Kv7 channels in
xiv

allergen-sensitized guinea pig ASMCs reveal a trend indicating a decrease in the
expression of all KCNQ (genes encoding Kv7 channels) isoforms in allergensensitized guinea pig airways compared to the saline-treated control animals. This
decreased Kv7 channel expression would be expected to cause greater membrane
depolarization and increased contractility of airways to various stimuli, common
feature of AHR. To investigate the function of Kv7 channels in ASMCs we further
conducted ex vivo studies using precision-cut lung slices (PCLS). Consistent with the
existing scientific literature, our PCLS demonstrate that the guinea pig airways
become hypersensitive to bronchoconstrictor agonists post-bronchial provocation,
with an increase in potency and magnitude of constriction in response to
bronchoconstrictor agonist treatment. Importantly, our studies also reveal that this
increased,

hypersensitive

response

of

allergen-sensitized

airways

to

bronchoconstrictor agonists can be attenuated by treatment with the clinically used
Kv7 channel activator, retigabine. This protective effect of a Kv7 channel activator is
likely due to an increase in activity of remaining Kv7 channels in allergen-sensitized
airways, thereby improving control on membrane polarization.
In summary, our observations reported in this thesis provide new insights
into how Kv7 channel expression and function in airways play a vital role in
regulating airway diameter. Importantly, the attenuation of bronchoconstrictor
agoinst-mediated airway constriction by a clinically used Kv7 channel activator in
allergen-sensitized airways as observed in our studies provides a promising new
strategy for treatment of AHR in asthma or other airway diseases.
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CHAPTER 1
PATHOPHYSIOLOGY OF ASTHMA
Asthma continues to be one of the major global health problems. According
to a recent update from the World Health Organization (WHO), approximately 235
million people in the world currently suffer from asthma (WHO fact sheet, 2011). A
recent national health statistics report indicates that the prevalence of asthma is on
the rise in the United States with 24.6 million people (8.2% of American population)
currently diagnosed with this disease (Akinbami et al. 2011). Asthma is also the
most common chronic disease afflicting children with its prevalence in children
being higher than that in adults.
The current therapy for asthma, constituting mainly the inhaled
corticosteroids and the long-acting inhaled β2-agonists, is effective and relatively
inexpensive, but also has a number of limitations. Primarily, it is a general strategy
targeted toward controlling and containing asthma by suppressing its symptoms. A
significant variability in patients’ responses to the current therapies has been
reported, especially in the case of inhaled corticosteroids (Szefler et al. 2010).
Severe cases of asthma accounting for approximately 10 % of the patient population
are mostly untreatable with the current lines of treatment. Hence the quest for
newer, more specific and curative therapies for asthma still continues. These
therapies are likely to emerge from novel drug classes that act on biological targets
1
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specific to asthma. Such specific and druggable asthma targets can only be identified
via in-depth understanding of the pathophysiology of this heterogeneous and
complex disease. Tremendous efforts are currently underway to discover complex
molecular pathways that underlie asthma symptoms (Holgate et al. 2011), however,
the pathophysiology of asthma still remains poorly understood.
According to current understanding, the three fundamental components in
pathogenesis of asthma are airway inflammation, airway remodeling and airway
hyperresponsiveness (AHR), which together lead to a progressive decline of normal
lung function (Bousquet J et al. 2000). AHR is defined as excessive contraction of
airway smooth muscle cells (ASMCs) in response to a variety of stimuli. A number of
different pharmacological, chemical and physical stimuli lead to such an
exaggerated response. However, the molecular mechanisms underlying AHR remain
unclear. Elucidating the molecular mechanisms of AHR will undoubtedly provide
better insight into this intricate process while simultaneously uncovering novel
therapeutic targets for improved treatments in asthma.
Regulation of calcium signaling in ASMCs
It is well known that intracellular calcium regulation plays a central role in
ASMCs contraction (Armani Y et al. 2002). An increase in the cytosolic calcium
concentration ([Ca2+]cyt) triggers bronchoconstriction. Various bronchoconstrictor
agonists like acetylcholine (ACh), leukotriene D4 (LTD4), endothelin and histamine
activate the Gq/11-coupled receptors on ASMCs leading to an increase in [Ca2+]cyt
(Penn et al. 2008). The local concentrations of these bronchoconstrictor agonists
have been found to elevate during ASMC hypercontraction (Belmonte 2005; Smith
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et al. 2005; Hamid Q et al. 2009). Studies have shown that the exposure of ASMCs to
these bronchoconstrictor agonists results in a biphasic elevation of [Ca2+]cyt (Hirota
et al. 2007; Jude et al. 2008) (Figure 1). The initial rapid or transient phase of
[Ca2+]cyt elevation is mediated by release of calcium from inositol-1,4,5-triphosphate
(IP3)-sensitive intracellular calcium stores also called sarcoplasmic reticulum (SR).
This transient increase in [Ca2+]cyt is usually followed by a sustained elevation of
[Ca2+]cyt that is maintained by influx of Ca2+ across the plasma membrane from the
extracellular space. This sustained elevation of Ca2+ plays an important role in
prolonging ASMC contraction. Influx of Ca2+ is believed to occur via several ion
channels on the surface of ASMCs. There are differences in opinion about the
contribution of various Ca2+ ion channels on ASMCs in agonist-mediated Ca2+ influx
(Janssen et al. 2002). In general, two mechanisms being debated are the voltageindependent calcium influx and voltage-dependent Ca2+ influx (Hirota et al. 2007).
The voltage-independent calcium influx is proposed to happen via store-operated
calcium channels (SOCC), receptor-operated calcium channels (ROCC) and/or nonselective cation channels belonging to the Transient Receptor Potential (TRP)
channel family. The influx of Ca2+ through SOCC can be triggered by the emptying of
internal Ca2+ stores (SR) (Ay et al. 2004), while the ROCC can be directly activated
by the diacylglycerol (DAG) produced as a result of agonist-mediated activation of
membrane receptors (Murray et al. 1993). The TRP family of channels have been
shown to be involved in Ca2+ influx in other types of smooth muscle cells. A similar
role was proposed for them in ASMCs after they were found to be expressed in
human ASMCs (Ong et al. 2004; Gosling et al. 2005; Perez-Zoghbi et al. 2009).
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Voltage-dependent calcium influx in ASMCs is proposed to proceed via voltage
sensitive calcium channels (VSCC), similar to the process in other smooth muscle
cells (Perez-Zoghbi et al. 2009). There is evidence, both in support and against
significant contributions of these different channel subtypes to the sustained phase
elevation of Ca2+.
various bronchoconstrictor agonists
(ACh, LTD4, Endothelin, Histamine)

ROCC

Gq/11

ASMC

PLC

TRP

VSCC

DAG

Ca+2

IP3

SOCC

Ca+2

Ca+2

Ca+2

sustained
phase

Na+

SR
Ca+2

transient
phase

CaM

MLCK

Bronchoconstriction

Figure 1: Regulation of calcium signaling in Airway Smooth Muscle Cells (ASMCs).
Bronchoconstrictor agonists bind to their receptors on ASMCs leading to activation of phospholipase
C (PLC) followed by synthesis of inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) from
membrane lipids. IP3 in turn stimulates the release of Ca2+ from the sarcoplasmic reticulum (SR)
followed by repetitive release and uptake of Ca2+ resulting in Ca2+ oscillations. Calcium influx across
the plasma membrane (sustained phase) may then occur via a number of Ca2+ channels like Store
Operated Calcium Channels (SOCC), Receptor-operated calcium channels (ROCC), Transient Receptor
Potential (TRP) family of channels and voltage sensitive calcium channels (VSCC). Elevated ca2+ by
these two mechanisms binds to calmodulin (CaM), thereby activating myosin light chain kinase
(MLCK), which phosphorylates MLC and initiates actomyosin cross-bridge cycling thus leading to
bronchoconstriction. The individual contribution of these channels in Ca 2+ influx during the sustained
phase is still under debate.

5

Ca2+

influx via VSCC on ASMCs
VSCCs open (activate) in response to membrane depolarization. VSCCs on

ASMCs have threshold for steep voltage-dependent activation ranging from -45 to 25 mV, with maximal activation at 0 to +20 mV (Figure 2). They are known to be
blocked by dihydropyridine based compounds (Hirota et al. 2007). All these
properties resemble the characteristic properties of “L-type” or long-lasting voltagesensitive calcium channels. The resting membrane potential (Em) of ASMCs ranges
from -60 to -45 mV (Liu et al. 2005), so it is unlikely for L-type VSCC to be
appreciably active at the resting state of the ASMC membrane. However, membrane
depolarization is likely to result in activation of L-type VSCC and influx of Ca2+. In
fact, many bronchoconstrictor agonists depolarize the ASMC membrane to
potentials positive to the L-type VSCC activation threshold (Hirota et al. 2007).
Therefore, L-type VSCC are likely to be the key contributors toward the influx of Ca2+
from the extracellular space into the cytoplasm, eventually leading to
bronchoconstriction. There is ample evidence in the literature supporting
involvement of L-type VSCC in elevating [Ca2+]cyt (Jude et al. 2008; Perez-Zoghbi et
al. 2009), particularly at low agonist concentrations (Barnes et al. 1985). A number
of studies have also shown that agonist-induced Ca2+ signaling in ASMCs is
attenuated by L-type Ca2+ channel blockers (Solway et al. 1985; Thirstrup et al.
1997; Hirota et al. 2003) emphasizing the role played by L-type VSCC in the calcium
influx during the sustained phase of agonist induced airway constriction.
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membrane depolarization by
bronchoconstrictor agonists
Resting
Em
of
ASMCs

-60

-50

L-type Ca+2
currents

-40

-30

-20

-10

0

Membrane Potential, mV
Figure 2: Resting membrane potential on ASMCs and threshold for activation of L-type VSCC
depicting their role in mediating influx of Ca +2 from extracellular space upon membrane
depolarization by bronchoconstrictor agonists. The width of the cone reflects fractional magnitude of
Ca+2 current at a value of membrane potential (Em).

Therapeutic potential of calcium channel blockers has been evaluated
previously in a number of clinical trials (Fish et al. 1984). Results from these clinical
trials suggested that calcium channel blockers like verapamil and nifedipine were
effective in dilating airways, but only in a subset of patients. Administration of these
calcium channel blockers showed significant protection against bronchoconstriction
induced by exercise, hyperventilation, histamine and methacholine (Barnes et al.
1983). Their therapeutic potential, however, was not fully explored mainly due to
their limited potency and systemic adverse effects.
K+ channels and their role in maintaining the Em on ASMCs
K+ channels play an important role in Ca2+ signaling through their ability to
maintain a negative membrane potential. As indicated before and depicted in figure
2, ASMCs have a resting membrane potential of -60 to -45 mV (Liu et al. 2005). In
human and guinea pig ASMCs the membrane potential is reported to oscillate in a
characteristic manner called slow waves (Small et al. 1982; Ito et al. 1989).
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However, these waves are rarely converted in to spiking action potentials as ASMC
membrane displays strong outward rectification under resting conditions. This
outward rectification is mainly in the form of K+ efflux via K+ channels on ASMC
membrane, thus maintaining a hyperpolarized state of the membrane (Thirstrup et
al. 2000). It therefore stands to reason that inhibition of K+ channels would result in
membrane depolarization and consequent activation of other voltage-dependent
channels on the ASMC membrane, including VSCC, which would promote Ca2+ influx
and ASMC contraction.
Based on this principle, our laboratory has previously reported such
mechanism for the Gq/11-coupled receptor pituitary hormone [Arg8]vasopressin
(AVP) in its vasoconstrictor actions on vascular smooth muscle cells (VSMCs). It is
generally accepted that AVP leads to vasoconstriction by the activation of PLC and
consequently the release of Ca+2 from SR. The half-maximal activation of PLC
requires nano-molar concentrations of AVP, however, the circulating AVP
concentrations are usually in the pico-molar range (Doyle et al. 1985). Our
laboratory observed that at physiologically relevant (low) concentrations, AVP acts
exclusively by activating the L-type VSCC in VSMCs (Henderson et al. 2007). It does
so by suppressing the activity of Kv7 channels via a protein kinase C (PKC) dependent pathway (Figure 3) (Brueggemann et al. 2007; Mackie et al. 2008a).
These results provide strong evidence for Kv7 channels playing a pivotal role in
maintaining a negative resting potential in the vascular myocytes and opposing the
opening of VSCC. Suppression of Kv7 channel activity by physiologically relevant
concentrations of AVP results in membrane depolarization and activation of VSCC.

8

Through the research presented in this thesis, we propose a similar mechanism for
bronchoconstrictor agonist-mediated ASMC contraction (please refer to chapter 2
for further discussion).
10 nM AVP
(high)

30 pM AVP
(low)
K+
Em
AVPR1a

PLC

VSMC

Kv7

L-type Ca+2

PLD

PKC

IP3

SR
Ca+2

Vasoconstriction

Figure 3: Two concentration-dependent signaling pathways of [Arg8] vasopressin (AVP) in
VSMCs. Nanomolar (nM) concentrations of AVP acutely activate the well-accepted AVP signaling
pathway that involves activation of phospholipase C (PLC) and inositol 1,4,5-trisphosphate (IP3)mediated calcium (Ca2+) release. On the other hand, picomolar (pM) concentrations of AVP induce
voltage-sensitive Ca2+ entry via protein kinase C (PKC) activation and inhibition of voltage-activated
K+ channels (Kv7).

Three different types of K+ channels are known to be expressed in ASMCs,
Ca+2-activated potassium channels (KCa+2), ATP-sensitive potassium channels (KATP)
and voltage-gated potassium channels (Kv) (Figure 4). Previous studies have shown
that KCa+2 channels do not contribute significantly toward controlling the Em on
ASMCs (Liu et al. 2003a). KCa+2 channel blocker used in the study had no effect on
resting membrane potential in rat ASMCs. Similarly, KATP channel inhibitor
glibenclamide showed no effect on Em under resting condition in rat and human
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ASMCs, indicating that KATP do not control the Em in ASMCs (Liu et al. 2003b; Zhao et
al. 2005).
(No effect on Em)

(No effect on Em)

K+

K+

KCa

ASMC

KATP

K+

Kv1

K+

~ -40 mV

Em = -45 to -60 mV

L-VSCC

~ -60 mV

Kv7

Ca+2

Figure 4: K+ channels and their role in controlling Em on ASMCs. Three different types of K+
channels are known to be expressed in ASMCs: KCa, KATP and Kv. Blocking the activity of KCa and
KATP channels has been shown to have no effect on the Em indicating that they do not govern the Em
on ASMCs. Evidences suggest that Kv channels are important determinants of E m, however, the Kv1
channels that were found to be expressed in ASMCs are not likely to contribute significantly to the
resting Em due to their relatively positive threshold of activation (-40 mV). Kv7 channel, on the other
hand, have threshold of activation that lies in the range of the resting Em on ASMCs making them
likely candidates governing the Em on ASMCs.

Kv channels are voltage-sensitive, Ca+2-independent K+ channels that are
considered the most important class of K+ channels in determining Em on ASMCs
(Hall et al. 2000). A few subtypes of Kv channels (Kv1.1, Kv1.2 and Kv1.5) have been
found to be expressed in human ASMCs (Adda et al. 1996). The threshold for
voltage-dependent activation of Kv1 channels lies positive to -40 mV. Contradictory
to literature reports, it seems unlikely for Kv1 channels with a relatively positive
threshold of activation to contribute to the resting membrane potential (-45 to -60
mV) on ASMCs. Kv7 channels, another type of voltage-activated potassium channels,
have a threshold for activation at ~ -60 mV. Hence, they seem more likely
candidates governing resting membrane potential on ASMCs compared to Kv1
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subtypes. However, their expression and function in ASMCs was largely unknown
before the start of the investigation presented in this thesis.
Structure, assembly and function of Kv7 channels
The Kv7 family of voltage-gated K+ channels is encoded by KCNQ genes. Five
subtypes have been identified so far: Kv7.1 – Kv7.5 (KCNQ1-5 as an alternative
terminology) (Gutman et al. 2003). Kv7 channels are composed of four subunits,
each consisting of six α-helical transmembrane domains (S1-S6) and a single P-loop
region (Figure 5). Of particular importance is the fourth transmembrane domain
(S4) that consists of regularly-spaced, positively-charged amino acids (arginine)
(Schroeder et al. 2000a), which plays an essential role in sensing membrane
potential and triggering conformational changes. The P-loop consists of potassium
signature sequence (TXXTXGYG) that serves as a characteristic feature of voltagegated K+ channels (Heginbotham et al. 1992).
Functional Kv7 channels require homomeric or heteromeric assemblies of
four subunits (tetramers). While the Kv7.1 (or KvLQT1) subtype has not been found
to co-assemble with other Kv7 subunits (Schwake et al. 2003), the Kv7.3 subunit has
shown the capability to form hetero-tetramers with all other subunits except for
Kv7.1 (Jentsch, 2000). Unlike other Kv channels, the tetramerization domain in Kv7
channels lies in the cytosolic C-terminus rather than the transmembrane domain 1
(Wehling et al. 2007). Besides this, the C-terminus also carries binding sites for
various regulatory elements such as phosphatidylinositol-4,5-bisphosphate (PIP2)
(Zang et al. 2003), calmodulin (CaM) (Yus-Najera et al. 2002), A-kinase anchoring
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protein (AKAP) (Hoshi et al. 2003), and phosphorylation sites for protein kinase C
(PKC) (Hoshi et al. 2003).
TXXTXGYG

P-loop

S1

S2

S3

+
+
+S4
+
+
+

Kv7.2
Extracellular

S5

S6

Intracellular

Kv7.2

Kv7.2
Kv7.3

Kv7.2–Kv7.3 tetrameric channel

Figure 5: Structural aspects of Kv7 K+ channels. (+) indicates the positively charged amino acid
arginine in transmembrane domain 4 (S4). TXXTXGYG is the potassium signature sequence in the Ploop region. The picture on the right shows assembly of Kv7.2-Kv7.3 hetero-tetrameric channel.

A particular distribution pattern has been observed for different subtypes of
Kv7 channels. Kv7.1 subtype has been found to be expressed predominantly by
cardiac myocytes, whereas Kv7.2–7.5 have been considered largely ‘neuronal'
(Jentsch, 2000; Schroeder et al., 2000a). The Kv7.4 subtype has been found to have
specialized cellular location in auditory neurons (Kharkovets et al., 2000). Adult rat
aorta and rat mesentric artery has been found to express Kv7.1, Kv7.4 and Kv7.5,
whereas only Kv7.5 was shown to be expressed in embroyonic rat aorta derieved
(A7r5) smooth muscle cells (Brueggemann et al. 2007; Mackie et al. 2008a). More
recently, Kv7.1 and Kv7.5 subtypes were also shown to be expressed in visceral and
myometrial smooth muscle (Jepps et al 2009; McCallum et al. 2008). Mutations in
the KCNQ genes encoding different Kv7 channel subtypes are known to be the
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underlying causes of various diseases. For example, mutations in Kv7.1 channels
result in cardiac arrhythmias, mutations in Kv7.2 and Kv7.3 result in neuronal
excitability (Jentsch, 2000), whereas mutations in Kv7.4 result in deafness (Robbins
et al. 2001). Therefore, different Kv7 channel subtypes have been found to be
attractive molecular targets for novel anti-epileptic (Main et al. 2000), anti-migraine
(Gribkoff 2003) and neuroprotective (Jensen 2002) agents.
As far as pharmacological regulation of Kv7 channels with synthetic small
molecules is concerned, a number of relatively selective Kv7 channel blockers and
activators have been developed over the years (Xiong et al. 2008). Chromanol 293B
is known as a selective Kv7.1 channel blocker (Busch et al. 1997; Schroeder et al.
2000b), although it also partially inhibits Kv7.5 currents at concentrations higher
than 100 µM (Lerche et al. 2000). Linopirdine (DuP 996, 1-phenyl-3,3-bis(pyridin-4ylmethyl)-1,3-dihydro-2H-indol-2-one) and its more potent analog XE991 (10,10bis(4-Pyridinylmethyl)-9(10H)-anthracenone) (Zaczek et al. 1998) are widely used,
relatively selective blockers of all Kv7 channels at concentrations below 10 µM
(Mackie et al. 2008b). At higher concentrations these compounds can potentially
block other types of K+ channels (Schnee et al. 1998). Among the Kv7 channel
activators, flupirtine (ethyl-N-[2-amino-6-(4-fluorophenylmethylamino)pyridin-3yl]carbamate) and retigabine (ethyl N-[2-amino-4-[(4-fluorophenyl)methylamino]phenyl]carbamate) have found wide usage. Flupirtine is used clinically as a nonopioid analgesic with muscle relaxant properties (Devulder 2010), while retigabine
is used as an anticonvulsant in the treatment of epilepsy (Harden 2012). Retigabine
selectively activates Kv7.2–7.5 at concentrations up to 100 μM, beyond which it also
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activates Kv7.1 channels (Tatulian et al. 2001; Schenzer et al. 2005; Wuttke et al.
2005). Our laboratory has recently shown that the cyclooxygenase-2 (COX-2)
enzyme inhibitor celecoxib (Celebrex®), and its COX-2 independent structural
analog 2,5-dimethylcelecoxib (DMC) (Schönthal et al. 2008), dramatically enhanced
Kv7 K+ currents and suppressed L-type VSCC channels in A7r5 rat aortic smooth
muscle cells (Brueggemann et al. 2009). But another popular COX-2 inhibitor,
rofecoxib (Vioxx®, withdrawn from the market), which is known to have adverse
cardiovascular effects upon long-term treatment, did not show enhancement of Kv7
K+ currents. These findings provides a likely mechanistic basis for differential
cardiovascular risk profiles of COX-2 enzyme inhibitors used as non-steroidal antiinflammatory drugs (NSAID).
Biophysical and pharmacological characterization of K+ currents in ASMCs
In parallel to the investigation presented in this thesis on expression and
function

of

Kv7

channels

in

ASMCs,

our

laboratory

has

carried

out

electrophysiological characterization of K+ currents in ASMCs with an objective to
detect Kv7 currents in ASMCs, and determine their contribution to the total currents
from all voltage-dependent potassium channels (Kvtotal) in ASMCs. Among the
typical characteristic features that differentiate Kv7 currents from other Kv currents
is that they display slow activation and deactivation kinetics, Kv7 channels typically
display very little or no deactivation even during sustained depolarization, and
some exibit a relatively negative threshold of activation (Jensen et al. 2007; Mackie
et al. 2008b). The non-inactivating nature of Kv7 channels is considered
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fundamental to their role in stabilizing the resting membrane potential in excitable
cells like neuronal cells.
In order to detect and measure the contribution of Kv7 currents in ASMCs,
our laboratory recorded K+ currents in freshly dissociated guinea pig and human
ASMCs. The whole cell perforated patch configuration was used to measure
membrane currents under voltage-clamp conditions. Amphotericin B was added to
the internal solution for membrane patch perforation. To isolate Kv7 currents, if
present, 100 µM gadolinium(III) chloride (GdCl3) was added to external solutions
based on the methods already developed in our laboratory (Brueggemann et al.
2007; Mackie et al. 2008a). Use of 100 µM GdCl3 reversibly shifted the V0.5 activation
of 4-aminopyridine sensitive Kv currents to more positive voltages, thus enabling
measurements of purely Kv7 currents at voltages negative or equal to -20 mV. The
currents recorded from guinea pig ASMCs (at voltages ≤ -20 mV) showed all the
characteristic features of Kv7 currents: (i) slow kinetics of activation with no
apparent inactivation during a 5s voltage step (Figure 6A); (ii) voltage-dependent
activation with a very negative threshold (~ -60mV) and a half-maximal potential of
activation (V0.5) of ~-31 mV (Figure 6B; Figure 7C & 7E); (iii) reversible
enhancement by selective activators of Kv7.2-7.5 channels, flupirtine and retigabine,
accompanied by a shift of the activation curve to more negative voltages (Figure 7);
(iv) complete and irrever-sible suppression by the Kv7 channel blockers linopirdine
(Figure 7B & 7D) and XE991 (Brueggemann et al. 2012). As discussed earlier,
neuronal and vascular Kv7 channels are known to be inhibited upon activation of
Gq/11-coupled receptors (Delmas et al. 2005; Mackie et al. 2008a). After biophysical
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and

pharmacological

characterization

of Kv7 currents in guinea pig ASMCs, our laboratory was interested in testing the
ability of Gq/11-coupled bronchoconstrictor agonists (methacholine and histamine)
to suppress the Kv7 currents in guinea pig ASMCs. A rapid and near complete
inhibition of Kv7 currents was observed upon application of 100 nM methacholine.
However, the currents were partially restored within 1-2 min to about 40% of the
control levels while methacholine was still present (Figure 8A). Approximately
60% reduction of Kv7 currents was observed at all voltages positive to -24mV as a
sustained effect of methacholine in 100 nM concentration (Figure 8B & 8E). Most
importantly, treatment with Kv7 channel activator flupirtine (10 µM) was found to
restore the amplitude of Kv7 currents post-methacholine suppression to 64% of
control (Figure 8B & E). Repeating these studies with histamine, another
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Figure 6: Biophysical characterization of K+ currents in guinea pig ASMCs. A. Representative
traces of the current recorded using a 5s voltage step protocol depicted below (from -64 mV holding
voltage, cell capacitance (C) = 15 pF). B. Averaged fractional conductance plots calculated from
steady-state Kv7 currents fitted to a Boltzmann distribution (V0.5 = -31.0 ± 1.5 mV, n=13). (Adapted
from: Brueggemann LI, Kakad PP, et al. (2012) Am J Physiol Lung Cell Mol Physiol 302(1):L120-132).
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protocol from -4 mV holding voltage. B. I-V relationships of Kv7 currents recorded in ASMCs before
(control, filled circles, n=5), after 5 min treatment with 10 µM flupirtine (open circles, n=5) and after
5 min treatment with linopirdine (10 µM, filled triangles, n=5). C. Averaged fractional conductance
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Averaged fractional conductance plots calculated from steady-state Kv7 currents measured in ASMCs
in control (filled circles,) and in the presence of 1 µM retigabine (open circles) fitted to a Boltzmann
distribution. (Adapted from: Brueggemann LI, Kakad PP, et al. (2012) Am J Physiol Lung Cell Mol
Physiol 302(1):L120-132).

17

A

B

100 nM methacholine

I, pA/pF

control
100nM MC
10mM XE 991

10mM F

0.8
0.6

Iat -20mV, pA

6
0.4
4
2
0

-80

2 min

D

C
3

-60

-40

-20

0 V, mV

I/Ic

control
30mM His
10mM XE 991

Histamine, mM
10
30

1.0

Iat -20mV, pA

10

5
0

-80

-60

-40

-20

0 V, mV

3 min

E

I/Ic at -20mV
1.0

*

*

0.5

#

#

0.0
C

His

His+ F XE 991

C

MC

MC+ F XE 991

Figure 8: Suppression of Kv7 currents by bronchoconstrictor agonists in guinea pig ASMCs
and their restoration by the Kv7 channel activator flupirtine (F). A. The time course of Kv7 current

inhibition was recorded in ASMCs, at -20 mV holding voltage in control (2 min) following by methacholine
application (100 nM for 3 min). After an additional 1 min recording flupirtine (10 µM) was applied in the
presence of methacholine (C= 21 pF, representative of 4 similar experiments). B. Average I-V relationships of
Kv7 currents recorded from -4 mV holding voltage in ASMCs before (control, filled circles, n=4), during
treatment with 100 nM methacholine (open circles, n=4) and in the presence of XE991 (10 µM, filled triangles,
n=3) applied in the end of each experiment. C. Dose-dependent suppression of Kv7 currents recorded at -20 mV
holding voltage was observed upon application of histamine (3-30 µM, indicated by arrows). D. Average I-V
relationships of Kv7 currents recorded from -4 mV holding voltage and normalized to control currents recorded
at +1mV in control (filled circles, n=4), in the presence of 30 µM histamine (open circles, n=4) and in the
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all other treatment (P< 0.05, one way ANOVA). (Adapted from: Brueggemann LI, Kakad PP, et al. (2012) Am J
Physiol Lung Cell Mol Physiol 302(1):L120-132).
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bronchoconstrictor agonist, showed suppression of Kv7 currents in airway
myocytes in a dose-dependent manner (Figure 8C). Histamine-induced Kv7 current
inhibition was transient at agonist concentrations from 1-10 µM, but application of
30 µM histamine induced sustained current inhibition at all voltages positive to -29
mV (Figure 8C-E). Subsequent addition of flupirtine (10 µM) in the continued
presence of 30 µM histamine completely restored remaining Kv7 current amplitude
to the values measured prior to histamine treatment (Figure 8E).
The electrophysiological studies discussed above from our laboratory
confirm the activity of Kv7 currents in ASMCs. They also showed that Kv7 currents
can be suppressed by Gq/11-coupled receptor agonists similar to other smooth
muscle cells. These results suggest that common signal transduction intermediates
are likely to be involved in the mechanism of suppression of Kv7 currents by Gq/11coupled receptor agonists in ASMCs. Following histamine and or methacholineinduced suppression of Kv7 currents, the current amplitude was restored to near
control values by flupirtine, indicating that flupirtine may either act by reversing the
blockage of Kv7 currents by bronchoconstrictor agonists, or by simply enhancing
the unblocked Kv7 currents. In either case, Kv7 channel activators show
tremendous potential in antagonizing the effect of bronchoconstrictor agonists on
airways in this preliminary study.
Summary
Asthma is a disease characterized by constriction of ASMCs with AHR being
an integral component of its complex pathophysiology.

Regulation of calcium

signaling is considered to be the key in understanding ASMCs contraction and
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relaxation. Influx of calcium from extracellular space is an important event that
leads to contraction of ASMCs. Several bronchoconstrictor agonists are known to
cause membrane depolarization that can lead to the opening of L-type VSCC, which
are considered to be the major contributors to bronchoconstrictor-agonist mediated
influx of calcium. Our laboratory has previously shown that Gq/11-coupled receptor
vasoconstrictor hormone AVP, in low, physiologically relevant concentration acts by
suppressing the activity of Kv7 channels, thereby leading to membrane
depolarization and activation of L-type VSCC. In other words, Kv7 channels are
determinants of resting membrane potential in VSMCs and their suppression can
lead to membrane depolarization. We envision a similar role for Kv7 channels in
ASMCs, wherein their activity is suppressed by bronchoconstrictor agonists to
mediate bronchoconstriction. However, expression and function of Kv7 channels in
ASMCs was largely unknown. The research presented in this thesis focuses on
detecting expression of various Kv7 channel subtypes in ASMCs, comparing their
expression pattern in normal and diseased airways, and determining the functional
role they play in airway modulation. The electrophysiological studies that were
conducted in parallel to this investigation have detected Kv7 currents in guinea pig
and human ASMCs. The Kv7 currents in guinea pig ASMCs are suppressed by
bronchoconstrictor agonists and were shown to be restored to near control levels
upon treatment with Kv7 channel activators. The expression and ex-vivo functional
studies presented in this thesis evaluate the potential of targeting Kv7 channels as
novel molecular targets for asthma therapy.

CHAPTER 2
PROJECT OVERVIEW
Objective
Airway Hyperresponsiveness (AHR) is the characteristic feature of asthma
pathophysiology, the molecular mechanisms of which are poorly understood. The
overarching goal of the research presented in this thesis is to elucidate the
mechanisms underlying AHR in asthma. This will not only help us gain a better
insight into the pathophysiology of asthma, but may further lead to the discovery of
novel and improved therapeutic agents. The primary objectives of this research are to
investigate the role played by a Kv7 K+ channels in pathophysiology of AHR, and to
explore the regulation of Kv7 channels as a novel therapeutic strategy in treatment of
asthma.
Rationale
Although Kv7 channels were considered to be primarily expressed in
neuronal cells, recent findings have revealed their expression in different excitable
cells like cardiac myocytes and vascular smooth muscle cells (VSMCs) (Joshi et al.
2006; Yeung et al. 2007; Brueggemann et al. 2007; Greenwood et al. 2009). The key
role attributed to Kv7 channels is the prevention of membrane depolarization by
stabilizing the negative membrane potentials on these cells (Mackie et al. 2008b).
Mutations in KCNQ genes encoding Kv7 channels have been shown to be linked to
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various high-impact diseases like cardiac arrhythmias, epilepsy and deafness. As
discussed in chapter one, our laboratory has discovered that Gq/11-coupled hormone
[Arg8]vasopressin (AVP) elicits its vasoconstrictor action by inhibiting the activity of
Kv7.5 channels in VSMCs via a PKC-dependent pathway (Brueggemann et al. 2007).
Findings from our laboratory have further suggested that the Kv7 channel activators
that are used clinically in management of neuronal disorders are effective in
reversing the vasoconstrictor effect of AVP in VSMCs (Brueggemann et al. 2007;
Mackie et al. 2008a). The crucial role played by Kv7 channels in VSMCs and other
excitable cells has motivated us to explore the significance of these channels in
airway smooth muscle cells (ASMCs) excitability.
Hypothesis
Our main hypothesis is that Kv7 channels play a critical role in maintaining
negative resting membrane voltages in ASMCs similar to other excitable cells, and
that bronchoconstrictor agonists promote ASMC contraction and airway narrowing
by suppressing the activity of Kv7 channels (Figure 9). We further hypothesize that
Kv7 channel activators will reverse the bronchoconstrictor agonist-mediated ASMC
contraction by restoring the activity of Kv7 channels.
K+

?
Kv7 channels

Airway Hyperresponsiveness (AHR)

Bronchoconstrictor
agonists

HYPOTHESIS

Airway Smooth Muscle Cell (ASMC)

Figure 9: Hypothesis for the research presented in this thesis.
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These hypotheses provide a pathophysiological basis for AHR in asthma and
will be tested by studies proposed in following two specific aims.
Specific Aim 1
Identify the Kv7 channel-subtypes expressed and compare their expression
profiles in normal and allergen-sensitized guinea pig ASMCs.
Specific Aim 2
Evaluate the efficacy of Kv7 channel activators in relaxation of allergensensitized guinea pig airways pre-constricted with bronchoconstrictor agonists
using precision-cut lung slices (PCLS).
Significance
Successful completion of this research will identify the subtypes of Kv7
channels that are predominantly expressed in normal and allergen-sensitized
guinea pig airways. The differences, if any, in the expression pattern of various
subtypes in normal and asthmatic ASMCs will provide us with important leads in
determining the role played by Kv7 channels in pathophysiology of AHR. The PCLS
studies will provide us with information on effectiveness of Kv7 channel activators
in relaxation of bronchoconstrictor agonist-mediated airway constriction. Overall,
the proposed research will not only probe into the unknown mechanisms for AHR in
asthma, but it is also likely to lead in to identification and pharmacological
characterization of Kv7 channels as novel targets for treatment of asthma.

CHAPTER 3
GUINEA PIG MODEL OF AIRWAY HYPERRESPONSIVENESS
Asthma is a prime example of a complex and multifactorial disease. It is also
a disease that is unique to humans as none of the commonly employed laboratory
animals naturally acquire the asthma-like syndrome that is endemic in humans.
Asthma, therefore, poses a considerable challenge for development of animal
models with symptoms that can accurately mimic those observed in human asthma.
Despite inherent challenges, various animal models of asthma have been developed
over the years that mimic several important symptoms observed in human asthma.
So far, asthma-like symptoms have been reproduced in animals like mice, rats,
guinea pigs, ferrets, dogs, sheep, monkeys and horses. However, each animal model
has its own advantages and disadvantages (Canning 2003).
Mice offer several advantages in the study of asthma compared to other
animals. Firstly, numerous inbred strains are available for mice compared to other
species. A detailed understanding of mouse genetics arguably improves its
suitability for employment of transgenic technology (Elias et al. 2003). Moreover,
numerous commercially available mouse-specific probes, immunological reagents,
growth factors, and cell surface markers are available for mice. Importantly, mice
have IgE as the primary allergic immunoglobulin similar to that found in humans.
However, there are considerable physiological differences between mice
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and humans that do not favor a straightforward extrapolation of asthma related
findings to humans. For example, unlike humans, mice do not exhibit spontaneous
AHR and have limited airway musculature (Shin et al. 2009). Additionally, human
airways have a larger diameter compared to mouse airways and different airway
diameter respond differently. Therefore, transposing data from mice to human
could be misleading (Kips et al. 2003). In fact it has been shown that human airway
responses to agonists are not similar to the responses in mouse airways (Held et al
1999) .These factors limit the use of mice as an animal model of asthma.
Guinea pigs are the animals most frequently used to model anaphylactic
(early, immediate type) bronchoconstriction. Guinea-pigs are readily sensitized to
ovalbumin (OVA) (Sundstrom et al. 2003) and it is easy to elicit a response to a
challenge that is similar to an asthmatic phenotype involving increased airway
responsiveness (Pretolani et al. 1996). To evaluate if they are a good model for
human airways, the response of isolated guinea-pig airways to pharmacological
agonists has been compared directly with humans (Muccitelli et al. 1987). This
study revealed that histamine and methacholine had comparable EC50 values and
showed similar maximal responses in both guinea pig trachea and human bronchus.
Notably, allergen-induced bronchoconstriction in guinea pigs and human bronchial
asthma have several features in common, and hence many important findings in
human asthma pathophysiology have emerged from the guinea pig model of asthma
(Szeleny I. 2000). Additionally, the potencies and efficacies of agonists and
antagonists have been found to be very similar in human and guinea pig airways
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(Canning et al. 2008). However, the guinea pig model also suffers from a few
disadvantages. The major anaphylactic immunoglobulin in guinea pigs is IgG1 as
compared to IgE in humans. Furthermore, there is a lack of guinea pig-specific
immunological and biochemical reagents, and there is also a shortage of inbred
strains. Therefore, genetic influences on susceptibility to sensitization and
development of airway disease are difficult to investigate in guinea pigs (Shin et al.
2009). However, weighing the successes of the guinea pig model in studying asthma
and asthma-related diseases, as well as the similarity to human airways in
responses to various bronchoconstrictor agonists, justifies our use of this animal
model for the studies presented in this thesis.
Animal Welfare and Housing
Male Hartley guinea pigs (250-350gm) were purchased from Elm Hill/Cady
Ridge Farms, and housed in a plexiglass cage (2 animals per cage) and fed ad libitum
in a regular 12-h dark/light cycle. All procedures described in this study were
approved by the Institutional Animal Care and Use Committee, Loyola University
Medical Center, Maywood, IL and were conducted in accordance with the Guide for
the Care and Use of Laboratory Animals (1996, National Academy of Sciences,
Washington D.C.)
Induction of AHR in guinea pigs
The stepwise protocol for induction of AHR in guinea pigs is as depicted in Figure
10. Young male guinea pigs (350-550 g) were given three intraperitoneal (i.p.)

26

injections of ovalbumin (OVA) (100 µg OVA and 100 mg aluminium hydroxide in 1
mL saline) or saline alone (control) on days 1, 3 and 5 (Mazzone SB et al. 2002).
young male (250-350 gm)

Day 1,3,5

i.p injection of ovalbumin (100 µg/mL
OVA and 100 mg Al(OH)3 in saline)

Day 6-18

Day 19

2 week sensitization period

exposed to fine mist of
ovalbumin (5 mg/ml for 30 min) or saline

Day 20,21

protocol repeated at 1
day interval for three trials

Figure 10: Flow chart depicting various treatment stages in the development of guinea pig model of
airway disease.

After a subsequent 2-week sensitization period, the animals were placed in a
cylindrical Plexiglas chamber where they were observed for at least 1 minute and
then exposed to a nebulized solution of OVA. This protocol was subjected to
optimization with different concentrations of OVA and duration of its exposure (see
troubleshooting section below). Finally, the animals were exposed to an optimized
concentration (5 mg/ml) of OVA in saline for 30 min using a commercial DeVilbiss
nebulizer with a constant pressure at ~0.3 ml/min (Smith et al. 2005). This protocol
was repeated at one day intervals for a total of 3 trials. Two days prior to the
exposure of aerosolized ovalbumin, the animals were acclimatized to fine mist of
saline under the same conditions. According to the published studies, this protocol
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should induce asthma attacks in a fairly uniform fashion. Ottenberg and coworkers
list the sequence of respiratory signs observed in this model as follows: “rapid
breathing, restlessness, chewing, ruffling of the fur, then labored breathing with the
use of accessory muscles of respiration, prolonged expiration, gasping, coughing,
dilation of alae nasi, and finally cyanosis and convulsion” (Ottenberg et al. 1958).
The allergen-sensitized guinea pigs were observed for measurement of the time of
onset of respiratory attack. The attack was characterized by the use of accessory
muscles for respiration, gasping, coughing, and pronounced respiratory distress.
Animals were closely monitored and any symptoms observed were recorded.
The animals were staggered in such a way that one animal was injected every
week starting with either saline control or allergen sensitized animal in the first
week and reversing the order with the next set of animals. The treatments and
schedules involved three i.p injections (saline or OVA) on Monday (Day 1),
Wednesday (Day 3) and Friday (Day 5) followed by exposure to aerosolized OVA on
Friday (Day 19), Saturday (Day 20) and Sunday (Day 21), i.e two weeks following
the last injection . The animals were then euthanized on the following Monday (Day
22) and the airway smooth muscle cells were isolated (see chapter 4 for detailed
procedures) from the upper part of the trachea for the expression studies. One half
of the surgically excised lung was inflated with agarose for preparation of slices (see
chapter 5 for detailed procedures). The other half of the lung was reserved to isolate
cells for the electrophysiological studies (not covered under this thesis).
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Troubleshooting
Our initial use of 10 µg/ml ovalbumin concentration to challenge guinea pig
following the 2 week sensitization period did not show the expected symptoms of
airway disease. A previous study using different concentration of ovalbumin (10
µg/ml, 100 µg/ml, 1 mg/ml, 5 mg/ml and 10 mg/ml) on five successive days
reported that 1mg/ml OVA induced symptoms like labored breathing, coughing and
rubbing of nose (Boichot et al. 1991). Based on this report, we modified our protocol
for OVA challenge, by increasing the aerosolized OVA concentration from 10 µg/ml
to 5 mg/ml. This concentration developed some of the symptoms like labored
breathing and gasping through the end of 15 minutes trial in allergen-sensitized
guinea pigs, but not in the saline control animals as expected. However, the most
severe symptoms (like prolonged expiration, coughing, dilation of alae nasi,
sneezing cyanosis and convulsion) were not observed in these animals. Based on
these observations and some additional published studies, we decided to prolong
the exposure time to 30 minutes (Lai et al. 2003; Ram et al. 2003).
Summary
In total, 4 saline control and 4 allergen treated guinea pigs were monitored in
a staggered fashion. The protocol for induction of AHR was revised (change in the
concentration of OVA challenge and exposure time) based on the observations made
during these studies. Optimization in the protocol led to the observation of some
important symptoms like labored breathing and gasping in the allergen sensitized
animals but not in the saline control animals.

CHAPTER 4
EXPRESSION OF Kv7 CHANNELS IN NORMAL AND ASTHAMATIC AIRWAYS
As discussed in chapter 1, Kv7 channel subtypes are found to be expressed in
a variety of excitable cells such as neuronal cells and vascular smooth muscle cells
(VSMCs), and play a pivotal role in controlling membrane excitability in these cells.
However, to our knowledge the expression of Kv7 channels in airway smooth
muscle cells (ASMCs) was previously unknown. Therefore, in order to investigate
the role of Kv7 channels in airway smooth muscle cells (ASMCs), it was essential to
know whether these channels are expressed in airways in the first place. Secondly, it
is known that particular subtypes of Kv7 channels are predominantly expressed in
specific tissues, for example, Kv7.1 subtype has been found to be expressed largely
in cardiac myocytes, whereas Kv7.2–7.5 have been found to be expressed mainly in
neuronal cells (Jentsch 2000; Schroeder et al. 2000a). So if Kv7 channels are
expressed in ASMCs, then we were also interested in measuring expression of
different subtypes of Kv7 channels in ASMCs. Finally, to achieve our objective of
exploring the role played by Kv7 channels in AHR, it is important to study and
compare the expression levels of Kv7 channels in normal and asthmatic airways.
Therefore, quantitative real-time reverse transcriptase-polymerase chain reaction
(qRT-PCR) studies were conducted in ASMCs obtained from normal, saline-control
and allergen-sensitized guinea pigs using primers specific for guinea pig KCNQ1-5.
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The availability of human tissues also led us to identify and measure the expression
levels of different Kv7 subtypes in human ASMCs (studies not a part of proposed
research). The use of human tissues for this study was reviewed and approved by
the Loyola University Chicago Institutional Review Board for the Protection of
Human Subjects.
Step 1: Isolation of Airway Smooth Muscle Cells (ASMCs)
The ASMCs from normal, saline-control and allergen-sensitized guinea pigs
were isolated using a method reported by Janssen and Sims (Figure 11) (Janssen et
al. 1992). In short, connective tissue, vasculature and innervation were removed
from primary and secondary bronchi. Bronchial segments 3-5 mm in length were
then transferred to ice cold physiological saline solution (PSS) containing in mM:
140 NaCl, 5.36 KCl, 0.34 Na2HPO4, 0.44 KH2PO4, 1.2 MgCl2, 0.05 CaCl2, 10 HEPES, 10
D-Glucose, pH adjusted to 7.2 with NaOH on ice, 298 mOsm/L. The segments were
then cut open and the epithelium was removed using a cotton-tipped applicator.
Each bronchial segment was cut into strips approximately 1 mm wide. The
bronchial strips were then transferred into PSS (pH adjusted to 7.2 with NaOH at 37
°C) supplemented with BSA (1 mg/ml), collagenase Type VIII (400 units/ml), papain
(30 units/ml), and DL-dithiothreitol (1 mM). The strips were then incubated for 4560 min at 37 °C. After enzymatic digestion, the tissue was washed 3-5 times with ice
cold PSS and gently triturated with a fire-polished Pasteur pipette to release
individual myocytes. After trituration of the tissue, remaining undigested pieces
were removed and ASMCs were pelleted by centrifugation (5 min at 2000 g). The
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cells were then stored at -20 °C in a Qiagen RNAeasy

plusTM

lysis buffer (350 µL lysis

buffer with 1 % β-mercaptoethanol) and used as required for qRT-PCR studies.
guinea pig
trachea with
lung in saline
solution

connective tissue,
vasculature and
innervation removed

segments of bronchi
opened and
epithelium removed

transferred into
solution of
collagenase and
papain

Segments of bronchi
cut into strips of 12mm

enzymatic digestion in
incubator at 37 C for
40 min

Figure 11: stepwise procedure for isolation of guinea pig ASMCs.

Human tracheal tissue was obtained from discarded lung transplant donor
tissue and trachealis muscles were dissected from the trachea in ice cold dissecting
solution and cut into strips approximately 2 mm in diameter. Strips of muscle were
then transferred to ice cold PSS and then into PSS at 37 C (pH adjusted to 7.2 with
NaOH at 37 C) supplemented with BSA (1mg/ml; fraction V, Roche Diagnostics
USA), collagenase Type VIII (950 units/ml; Sigma), papain (38 units/ml;
Worthington), and DL-dithiothreitol (1 mM; Sigma). The strips were then incubated
for 45 min at 37 C. After enzymatic digestion, the tissue was washed 3-5 times with
ice cold PSS and gently triturated to release individual myocytes.
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Step 2: qRT-PCR studies in (normal, saline-control and allergen-sensitized)
guinea pig ASMCs and normal human trachealis muscles
qRT-PCR was used to determine the expression of KCNQ1–5 in guinea pig
ASMCs and human trachealis muscle. ASMCs were isolated as described above from
smooth muscle dissected free from the entire trachea. The cells (or trachealis
muscles) so obtained were disrupted and homogenized using a Polytron
homogenizer for 30 Seconds. Total RNA was extracted from ASMCs by use of RNeasy
Plus Mini Kit (Qiagen, Valencia, CA). The RNA purified with a RNeasy silicamembrane method, is expected to remove most of the genomic DNA contamination
efficiently. The RNA so obtained was not further treated with DNAase. RNA was
quantified using a NanoDrop spectrophotometer, and the mRNA was reverse
transcribed with a Bio-Rad iScriptTM cDNA synthesis kit. The cDNA thus obtained
was amplified in a qRT-PCR reaction by using primers specific for guinea pig
KCNQ1–3, 5 (Navarro-López et al. 2009) and KCNQ4 (Liang et al. 2006) (Table 1).
Quantitative expression was performed with Applied Biosystems 7300 Gene
Expression System in 25 µl reactions consisting of 12.5 µl MaximaTM SYBR
Green/ROX qPCR Master Mix (Fermentas, Burlington, Ontario, Canada), cDNA
derived from 25–250 ng mRNA, and 5 pmol each primer. Cycle parameters were
typically 95°C for 15 s, followed by 60°C for 30 s (40 cycles), and followed by a
dissociation step to confirm a single PCR product. Specificity of the PCR primers was
also verified by DNA sequencing. Standard curves were plotted by 10-fold serial
dilution of known amounts of cDNA for each target. Primer efficiencies were
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determined from the slope of the standard curve dilution series for each of the
KCNQ targets, by using the formula Efficiency = 1+10(1/slope). The correlation
coefficients for all standard curves were >0.99, and slope values gave efficiencies
90% in all cases. The target copy number in a sample was estimated by relating the

PCR threshold cycle to the known target value on the standard curve. The mRNA
levels of KCNQ1–5 were averaged from four male guinea pigs (250–350 g) with each
reaction performed in duplicate. RNA extracted from one guinea pig ASMC sample
was reverse transcribed as described above for end point PCR to confirm PCR
product sizes for each primer pair. cDNA was amplified by using Platinum Taq PCR
Mix (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol and
conventional PCR cycle parameters of 95°C for 1 min, 50°C for 1 min (30 cycles), and
final extension at 72°C for 5 min. The PCR products were separated by agarose gel
electrophoresis and the gel was visualized and imaged by use of a BioImaging
System (UVP, Upland, CA).
Human trachealis RNA was extracted from human donor lung trachealis
muscle (cut into 2 mm - 5 mm pieces; 4–5 pieces per human sample) by the acidguanidinium-phenol extraction method (Chomczynski et al. 1987). Reverse
transcription was carried out as above, and qRT-PCR was performed with primer
pairs specific for human KCNQ genes (Ng et al. 2011) (Table 2). To determine if the
RNA sample was contaminated with genomic DNA we included a no reverse
transcriptase control in the real time PCR. The PCR end products (plus/minus RT)
were than allowed to run on an agarose gel. All the minus RT samples except KCNQ4
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showed absence of band confirming that the RNA samples were free of genomic
DNA. However, the RNA samples were not treated with DNase for further
purification. Each reaction was performed in triplicate for at least four individuals,
and KCNQ1–5 transcript copy numbers were estimated as described above for
guinea pig, by comparing to standard curves constructed for each of the human
KCNQ gene targets.
Table 1: Guinea Pig Primers

Gene

Primer Sequence

Product size (bp)

KCNQ 1

F:5’-ATTGTCCTGGTGGTGTTCTTTG-3’
R:5’-CCCCTGATGGCTGATGTGG-3’

KCNQ 2

F:5’-TCTACGCCACCAACCTGTC-3’
R:5’-TACATGGGCACCGTGACC-3’

79

KCNQ 3

F:5’-CTTGAAAACCGTCATCTGC-3’
R:5’-CAAGTTCACAGGGTCGTG-3’

124

KCNQ 4

F:5’-GGGCCTCTCTAAGACTCAAG-3’
R:5’-AGGTGTCCTGCTGAATACTG-3’

235

KCNQ 5

F:5’-CGTCCGCACTCAGAAGTC-3’
R:5’-TCCAATGTACCAGGCTGTG-3’

137

206

Table 2: Human Primers

Gene

Primer Sequence

Product size (bp)

KCNQ 1

F:5’-AACCTCATGGTGCGCATCA-3’
R: 5’-CCGCGATCCTTGCTCTTTT-3’

100

KCNQ 2

F: 5’-GGAAACCGTTCTGTGTGATTGAC-3’
R:5’-TCCGCAGAATCTGCAGGAA-3’

128

KCNQ 3

F:5’-CCACGCCAAAACACAAGAAGT-3’
R: 5’-TGATGTGGATGGTCTGGCTACA-3’

100

KCNQ 4

F: 5’-GCGACCGTACGACGTGAAG-3’
R: 5’-CAATTTGGTCCACCCGAGTT-3’

100

KCNQ 5

F: 5’-TCCCTGAGCACACAAAATTGG-3’
R: 5’-CCCGCAGACCAGATTCGA-3’

102

F=Forward; R= Reverse
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Results
Expression of multiple Kv7 channel subtypes in normal guinea pig and human ASMCs:
The qRT-PCR expression studies using primers specific for guinea pig and human
KCNQ1-5 revealed expression of multiple subtypes of Kv7 channels in normal
guinea pig and human ASMCs. The expression pattern in normal guinea pig ASMCs
was as follows: KCNQ2>KCNQ5>KCNQ4>KCNQ3>>KCNQ1 (Figure 12A). The
ASMCs from human trachealis muscles revealed a more variable pattern of
expression, with abundant expression of KCNQ1, no detectable expression of KCNQ2
and KCNQ3, and modest expression of KCNQ4 and KCNQ5 (Figure 12B). The
products were also confirmed by sequencing.
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Figure 12: Multiple KCNQ subtypes are expressed in guinea pig and human airway smooth
muscle cells (ASMCs). Expression levels of mRNAs for KCNQ1-5 were estimated using quantitative
real time RT-PCR in guinea pig airway myocytes (A) and human trachealis muscle (B). Average ng
target (normalized to ng input of RNA) mRNA ± SEM from n=4 guinea pigs and from n=4 human
trachealis muscle samples. (Brueggemann LI, Kakad PP, et al. (2012) Am J Physiol Lung Cell Mol
Physiol 302(1):L120-132).
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Figure 13: Immunohistochemistry studies supporting expression of Kv7 channels in airways.
Immunostaining of guinea pig trachealis myocytes (C) and human trachealis myocytes (D) stained
with anti-Kv7.1–7.5 antibodies (top rows); and stained with Kv7.2 and Kv7.3 antibodies preincubated
with the corresponding blocking peptide (anti-Kv7.2 BP; anti-Kv7.3 BP) (bottom rows). Cells
processed for imaging without primary antibody (1° control) show no detectible fluorescence in
ASMCs at the same gain and intensity settings (right). (Brueggemann LI, Kakad PP, et al. (2012) Am J
Physiol Lung Cell Mol Physiol 302(1):L120-132).

The expression of multiple Kv7 channel subtypes in guinea pig and human
ASMCs was also supported by immunohistochemistry studies (outside the scope of
proposed studies; carried out by Dr. L. Brueggemann) (Figure 13). The
immunohistochemistry studies are not quantitative and hence we did not attempt to
compare the expression levels in guinea pig and human ASMCs. Our sole objective
was to confirm the expression of translational gene products. Our studies thus
provide the first evidence of expression of Kv7 channels in guinea pig and human
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airways, thus paving the path for further exploration of their role in AHR. Our next
step was to compare the expression pattern of different Kv7 channel subtypes in
asthmatic guinea pig ASMCs.
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Figure 14: Comparing expression pattern of different Kv7 channel subtypes in saline-control
and allergen-sensitized guinea pig ASMCs. Expression levels of mRNAs for KCNQ1-5 were
estimated using quantitative real time RT-PCR in saline-control guinea pig ASMCs ( ), and allergensensitized guinea pig ASMCs ( ). Average ng target mRNA ± SEM from n=4 saline-control guinea pig
ASMCs and n=4 allergen-sensitized guinea pig ASMCs.

Differences in expression pattern of Kv7 channel subtypes in saline-control and
allergen-sensitized guinea pig ASMCs: In these preliminary studies comparing
expression of different Kv7 channel subtypes in saline-control and allergensensitized ASMCs (Figure 14), an interesting trend was observed: expression of all
KCNQ channel subtypes was found to be decreased in allergen-sensitized guinea pig
ASMCs. In these initial studies, ASMCs from four saline-control and allergensensitized animals were used. The decrease in expression of Kv7 channel subtypes
however, was not statistically significant, due to a variety of reasons. Firstly, the
number of animals used in the study was not sufficient (power of comparison below
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0.80) to obtain significant results due to high variability inherent to animal studies.
Secondly, the four allergen-sensitized guinea pigs used for isolation of ASMCs
received different amount of allergen treatment as these animals were mostly from
the optimization studies we performed in the animal model preparation. Therefore,
these studies need to be repeated with ASMCs from allergen-sensitized guinea pigs
receiving now-optimized allergen treatment. However, if a decreased expression of
KCNQ subtypes in allergen-sensitized guinea pigs is reproducibly observed, this will
have important implication for our understanding of the etiology of AHR. Also, the
reason for differences in the expression pattern of Kv7 channel subtypes between
saline-treated and normal guinea pigs is unclear. This could be possibly attributed
to the inherent inter-animal variability. We expect to see diminished variability as
the number of animals is increased in our future studies.

CHAPTER 5
FUNCTIONAL ROLE OF Kv7 CHANNELS IN AIRWAYS
Our qRT-PCR studies not only revealed the expression of different Kv7
channel subtypes in guinea pig and human ASMCs for the first time, but also
provided preliminary evidence that the expression of different subtypes of Kv7
channels is decreased in allergen-sensitized guinea pig airways. These results
support our hypothesis that Kv7 channels have an important role to play in normal
airway function, which is affected in asthmatic airways. Therefore, our next goal was
to determine the functional relevance of these channels in normal and diseased
airways. There are several in vitro models such as the tracheal or bronchial rings
and parenchymal smooth muscle strips, that have been used to study the airway
function. However, precision-cut lung slices or PCLS offer many advantages
(Henjakovic et al. 2008; Liberati et al. 2010).
narrowing

responses

and

the

Using PCLS, functional airway

concentration-dependent

responses

to

bronchoconstrictors and bronchodilators can be directly observed and recorded
with a high degree of accuracy. PCLS preparations maintain cell–cell and cell–matrix
relationships reproducing many properties and functions of the whole organs,
therefore serving as an excellent ex vivo alternative for in vivo studies. Moreover,
more than 30 lung slices can be prepared from one guinea pig lung and each animal
can serve as its own internal control. Therefore, this method provides a
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greater throughput for evaluating multiple drugs using fewer animals. However, a
major challenge for PCLS studies specific to guinea pig preparations is post mortem
airway constriction (Lai et al. 1984a). The cause of this post mortem constriction is
not fully understood but it is attributed to the release of substance P from sensory
neurons (Lai et al. 1984b). Ressmeyer and coworkers have reported a solution for
post mortem constriction by introducing isoproterenol in the media used for PCLS
preparation. It is suggested that once the PCLS preparation is complete,
isoproterenol use be discontinued. The isoproterenol effect is not sustained after
discontinuation and the slices respond normally to various treatments (Ressmeyer
et al. 2006).
Preparation of Precision-Cut Lung Slices (PCLS)
Chemicals: Histamine, methacholine(acetyl-β-methylcholine chloride), ovalbumin
and aluminium hydroxide required for PCLS studies were purchased from SigmaAldrich (St. Louis, MO). Retigabine dihydrochloride was purchased from LGM
Pharma (Boca Raton, FL). XE-991 dihydrochloride was from Ascent Scientific
(Princeton, NJ). Low melting point agarose was from GIBCO® (Invitrogen Corp,
Carlsbad, CA). Drugs were diluted as needed in the control vehicle (2 mM Ca+2
Physiological Saline Solution (PSS)) used for the precision-cut lung slices. Drugs
were used in a concentrations ranging from 1 nM to 10 µM.
Protocol: Post euthanasia (sodium pentobarbital overdose), a thoracotomy was
performed and the heart was excised to expose the bronchi. The lower half of the
trachea was cut and cannulated with a 1/16” polyethylene tube connector attached
to a 3-way stop-cock. One of the bronchi was tied off and that was reserved for
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electrophysiological studies. The cannulated tissue was then placed into a glass
beaker with mHBSS (modified-Hank’s Balanced Salt Solution (mM): NaCl 137.9, KCl
5.33, CaCl2 1.26, MgCl2 0.49, MgSO4 0.41, HEPES 20, KH2PO4 0.44, Na2HPO4 0.34, Dglucose 5, pH 7.4-NaOH at 37°C, 298-300 mOsm) preheated to 37°C in a water bath.
With a 10 mL syringe attached to one inlet, the lung was deflated. On the another
inlet of the stopcock there was a 10 mL syringe filled with low-temperature-melting
Type IX-A agarose (2 % in mHBSS supplemented with 20 mM HEPES). The agarose
solution also contained isoproterenol in varying doses (see troubleshooting section)
at 37 °C. The lung was inflated by injecting the warm agarose solution. After
inflating the lungs with warm agarose, 5 ml of air was injected using a second
syringe to push agarose into the alveoli from the airways. The inflated lungs were
then placed into a glass beaker containing ice cold mHBSS (pH 7.4 at 4°C) and
allowed to cool on ice for 30 minutes to solidify the agarose. The non-inflated lobe
was cut and used for isolation of airway smooth muscle cells (as discussed in
chapter 3). Precision-cut lung slices were made by use of a Leica VT 1200S
vibratome, while maintaining the lung at 4 °C. Lung slices (350 μm thick) containing
cross sections of 0.05– 0.5 mm in diameter, were incubated for 3 h in serum-free F12/ DMEM (Dulbecco's Modified Eagle Medium) tissue culture medium containing 1
µM isoproterenol, supplemented with ITS (Insulin-Transferrin-Selenium, Mediatech,
Manassas, VA) and antibiotics at 37°C under 5% CO2. Medium was changed after
every 30 minutes for 3 h. After 3 h, the slices were transferred to the same medium
but without isoproterenol. Lung slices generally remained viable for at least 4 days.
Slices containing airways were used only if 1) the airway was approximately
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circular; 2) beating cilia were observed (indicating an intact epithelium) and; 3) the
airway wall and all parenchymal attachments were intact. The selected lung slice
was then transferred into a 35 mm tissue culture dish onto a 25 mm diameter round
glass coverslip (sterilized by dipping in 100% ethanol and flame dried). The dish
contained 1 ml of 2 mM Ca2+ PSS (control medium (mM): 140 NaCl, 5.36 KCl, 1.2
MgCl2, 2 CaCl2, 10 HEPES, 10 D-glucose, pH 7.3, 298 mosmol/l).
Measurement of airway diameter: Vacuum grease was applied to the groove of a
customized recording chamber. A coverslip with a PCLS was positioned evenly into
the groove of the chamber. A silicon ring was gently placed on the coverslip in order
to avoid any leak. Finally, a platinum weight was placed on the slice so as to hold
the slice in position without blocking the view of the airway. The chamber was then
filled with 1 ml of the control medium. The glass bottom of the chamber was cleaned
with an alcohol soaked Kim-wipe®.

The lung slice, mounted in the perfusion

chamber was then placed on the stage of an inverted microscope (Olympus IX-71)
and visualized via a 10X objective. A cross section of a small bronchiole (0.05–1.5
mm in diameter) was positioned in the center of the microscopic field and the lung
slice was then equilibrated in control medium at room temperature for at least 30
min. Control medium, plus or minus drugs, was continuously superfused over the
lung slice via a gravity-fed perfusion system at a rate of ~5 ml/min, controlled by a
common flow regulator. Experiments were conducted at room temperature. The
focus and light intensity was adjusted to see the clear image. The region of interest
(ROI) for the measurement was selected (red outline). The threshold range that
identifies the object in green for measurement was then selected (Figure 15).
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Images were captured with a 12-bit digital camera (Hamamatsu Orca) at 5-s
intervals. Luminal area was measured by image analysis using Simple-PCI software
(Hamamatsu, Sewickley, PA). Summarized measurements of luminal area of the
airway in each experiment represent the average for the last 1 minute of drug
application or washout (total 12 measurements in each case).

Figure 15: Image demonstrating luminal area measurement of PCLS preparation. A cross
section of a small bronchiole (0.05–1.5 mm in diameter) is positioned in the center of the
microscopic field. The threshold range that identifies the object for measurement in green is selected.
Images are captured at 5-s intervals.

To obtain dose-response curves for bronchoconstrictor agoinsts (histamine
and methacholine) in saline-control and allergen-sensitized airways, the PCLS
preparations from these animals were treated with agonist concentrations ranging
from 1 nM to 30 µM. The dose-response studies were repeated in PCLS from
multiple animals and the data was then plotted as normalized area versus logarithm
of agonist concentration using Graph Pad Prism software. The half-maximal
effective concentration (EC50) was determined by fitting the data to five-parameter,
variable-hill slope equation.
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Troubleshooting
Following the procedure reported by Ressemeyer and coworkers to prevent
post mortem constriction,

1 µM isoproterenol in agarose solution was used

(Ressemeyer et al. 2006). However, the slices using this protocol did not respond to
any of the agonists tested and instead constricted or dilated spontaneously in the
control medium independently of the drug treatment. After a few repetitions with
similar outcome, we decided to omit isoproterenol from our experiments. This,
however, did not solve the problem. The slices obtained from these lungs did not
respond to any concentration of agonist. Instead a very stable baseline recording
was obtained independently of the treatment. A lower concentration of
isoproterenol (100 nM) in agarose was also tested. However, the problem persisted
despite use of the lower isoproterenol concentration.
Finally, we went back to the original protocol, using 1 µM isoproterenol in 2
% agarose solution to inflate the lungs. However, this time the slices were
maintained in medium containing 1 µM isoproterenol after preparation. This solved
the problem of post mortem constriction as well as the unusual behavior exhibited
by the guinea pig lung slices in the earlier studies.
Results
The physiological relevance of functional Kv7 channels in guinea pig airways was
investigated using PCLS studies. Before beginning our planned pharmacological
studies, we wanted to confirm the hypersensitivity of actively sensitized airways
obtained from the allergen-sensitized guinea pig model. This was done by
challenging these actively sensitized airways with ovalbumin (passive challenge).
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Application of 1 µg/ml ovalbumin alone completely closed the airways, providing
strong evidence that the airways of OVA-treated animals were indeed
hypersensitized. As observed from the time course (Figure 15), the airways started
GPLS asthma 051712_2

to relax while still in ovalbumin, this could be due to the depletion of the agonist
stores (methacoline, histamine), which cannot be resynthesized in the ex vivo model
of PCLS.
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Figure 16: Passive sensitization of airway from guinea pig model of AHR using ovalbumin
(OVA). Representative time course after treatment with 1 ug/mL OVA to PCLS preparations obtained
from actively sensitized guinea pig airways.

Increased sensitivity of allergen-sensitized airways to bronchoconstrictor
agonists: Our next goal was to evaluate the differences in response of saline-control
and allergen-sensitized airways to the bronchoconstrictor agonists, histamine and
methacholine. We expected increased sensitivity of allergen-sensitized airways to
bronchoconstrictor agonists. As expected, the allergen-sensitive airways showed
clear and distinct hyperresponsiveness to both histamine and methacholine. Our
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next step was to determine the half-maximal effective concentrations (EC50) for
these agonists in both saline-control and allergen-sensitized airways. The doseresponse curves for histamine (Figure 16) and methacholine (Figure 17), were
determined in saline-control and allergen-sensitized airways. As expected there was
shift in the dose-response curve toward left for allergen-sensitized airways
indicating increased sensitivity to bronchoconstrictor agonists. The observed EC50
value of 204.5 nM obtained from the dose-response curve of histamine in salinecontrol guinea pig airways was in a very good agreement with literature reported
value of 217 nM in normal guinea pig airways (Ressemeyer et al. 2006).
Importantly, there was ~4.5 fold decrease in the EC50 value (45.9 nM) observed in
allergen-sensitized airways thus providing clear evidence that AHR has been
induced in the guinea pig model. Dose-response curve for methacholine showed
~2.5 fold decrease in the EC50 value in allergen-sensitized airways (28.7 nM)
compared to saline-control guinea pigs airways (72.0 nM). Along with an increase in
sensitivity to histamine and methacholine in allergen-sensitized airways, a
considerable increase in Emax (maximal effect) was observed with both
bronchoconstrictor agonists tested (Figure 16C & 17C).
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Figure 17: Dose-response curves for histamine in PCLS preparations from saline-control and
allergen-sensitized guinea pig airways. A: representative images showing change in luminal area
of PCLS preparations after treatment with increasing concentrations of histamine (H) in salinecontrol (top) and allergen-sensitized (bottom) airways. B: corresponding representative time course
of changes in luminal area of the same PCLS preparations in saline-control (left) and allergensensitized (right) airways. C: Dose-response curve obtained by plotting the normalized luminal area
versus logarithm of histamine concentration in saline-control ( , n = 3) and allergen-sensitized (∎, n
= 2) airways. Half-maximal effective concentration (EC50) values were obtained by fitting the data to
the five-parameter, variable slope equation using GraphPad® Prism software (La Jolla, CA). Doseresponse curve for histamine in saline-control guinea pigs gave an EC50 = 204.5 nM that is in very
good agreement with literature reported value of 217 nM (Ressemeyer et al. 2006). The EC50 of
histamine in allergen-sensitized guinea pigs was calculated to be 45.9 nM.
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Figure 18: Dose-response curves for methacholine (MC) in PCLS preparations from salinecontrol and allergen-sensitized guinea pig airways. A: representative images showing change in
luminal area of PCLS preparations after treatment with increasing concentrations of MC in salinecontrol (top) and allergen-sensitized (bottom) airways. B: corresponding representative time course
of changes in luminal area of the same PCLS preparations in saline-control (left) and allergensensitized (right) airways after MC treatment. C: Dose-response curve obtained by plotting the
normalized luminal area versus logarithm of MC concentration in saline-control ( , n = 3) and
allergen-sensitized (∎, n = 2) airways. EC50 values were obtained by fitting the data to the fiveparameter, variable-slope equation using GraphPad® Prism software (La Jolla, CA). Dose-response
curve for MC in saline-control guinea pigs gave an EC50 = 72.0 nM, while the EC50 of MC in allergensensitized guinea pigs was calculated to be 28.7 nM.
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Figure19. Kv7 Channel activator retigabine (R) attenuated histamine (H)-induced constriction
of saline-control and allergen-sensitized airways. A: Representative images of a small airway
from saline-control and allergen-sensitized airways in the presence of 50 nM histamine (50 nM H)
alone, and 50 nM histamine applied with 10 µM retigabine after complete recovery from the first
treatment (50 nM H + 10 µM R). B: corresponding representative time course of changes in luminal
area of the same small airways. C: summarized bar graph of the percentage of 50 nM histamine
induced constriction after histamine + retigabine treatment, data normalized to 50 nM histamine
treatment. Luminal area was measured during the last min of treatment with 50 nM H and 50 nM H +
10 µM R.
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Kv7 channel activator attenuates histamine-induced bronchoconstriction in
guinea pig airways: After determining the EC50 values of histamine and
methacholine in saline-control and allergen-sensitized airways, we wanted to study
if the bronchoconstriction effect on allergen-sensitized airways can be attenuated
with Kv7 channel activators. Histamine was selected for these studies because it
showed a distinctly potentiated effect in allergen-sensitized airways. We treated
PCLS preparations from saline-control and allergen-sensitized airways with a near
EC50 concentration of histamine (50 nM) as measured in allergen-sensitized
airways. The 50 nM histamine treatment was repeated (after complete relaxation of
the airway) in the presence of 10 µM retigabine (Kv7.2-Kv7.5 channel activator)
(Figure 18A & B). Importantly, retigabine was able to attenuate the histaminemediated bronchoconstriction by ~20 % in saline-control airways and ~ 70 % in
allergen-sensitized airways (Figure 18C). This result is significant as it supports our
hypothesis

that

Kv7

channel

activators

can

attenuate

the

effect

of

bronchoconstrictor agonists in allergen-sensitized airways. These studies will be
repeated for reproducibility using PCLS preparations from a larger number of
animals. Vehicle control for retigabine will also be included.
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Figure 20. Functional Kv7 channels are required for maintaining resting diameter of small
airways in human lung slices. A: representative images of a small airway before treatment
(control), in the presence of 50 nM histamine applied for 5 min (50 nM Hist), in the presence of 50
nM histamine applied with 100 µM flupirtine for 5 min (50 nM Hist + 100 µM F), following a 10-min
washout of histamine and flupirtine (washout), and in the presence of 10 µM XE991 applied for 10
min. B: corresponding representative time course of changes in luminal area of the same small
airway. Both 50 nM histamine (Hist) and 50 nM histamine with 100 μM flupirtine (Hist + F) were
applied for 5 min followed by a 10-min washout in each case; 10 μM XE-991 was applied for 10 min.
C: summarized bar graph of average airway luminal area measured in multiple lung slices from 2
human subjects. Luminal area measured during the last min of treatment with 50 nM histamine
(Hist), 50 nM histamine with 100 µM flupirtine (Hist + F), or 10 µM XE991 was normalized to control
area measured before treatments; *significant difference from control (1-way ANOVA, P < 0.001, n =
6–8); #significant difference between histamine alone and histamine plus flupirtine treatment
groups (paired Student’s t-test, P < 0.05, n = 6). (Adapted from: Brueggemann LI, Kakad PP, et al.
(2012) Am J Physiol Lung Cell Mol Physiol 302(1):L120-132).

52

Kv7 channel activator attenuates histamine-induced bronchoconstriction in
human airways: The availability of human lung tissues enabled us to evaluate the
physiological relevance of functional Kv7 channels in human airways using PCLS
(work carried out by Dr. L. Brueggemann). Application of 50 nM histamine induced
a 41  10% constriction of human airways (as estimated by reduction of luminal
area). The histamine-induced constriction was slightly but significantly attenuated
(29  10%, P = 0.014, paired Student’s t-test) in the presence of 100 µM flupirtine,
an activator of Kv7.2–7.5 channels (Figure 19C). Application of 10 µM of XE991, a
potent and selective inhibitor of Kv7 channels, consistently induced near total
constriction of small airways (46–89 µm in diameter) in human lung slices (79  6%
constriction, n = 6; Figure 19).

CHAPTER 6
DISCUSSION AND CONCLUSIONS
Airway hyperresponsiveness (AHR), a characteristic feature of asthma, is
marked by increased sensitivity of airways to inhaled bronchoconstrictor agonists.
The mechanisms underlying AHR are, however, poorly understood. Airway smooth
muscle cells (ASMCs) are the main effector cells of airway narrowing. The Kv7
voltage-activated K+ channels are known to play an important role in regulating
resting membrane potential of many excitable cells, however, their expression and
function in ASMCs has never been investigated before. The research presented in
this thesis not only studies the expression and function of Kv7 channels in ASMCs
but also reveals a link between modulation of Kv7 channel function and AHR in
asthmatic airways. Our results present the first evidence of Kv7 channels expression
in guinea pig and human ASMCs. In a parallel investigation to these studies, our
laboratory

has

measured

K+

currents

in

ASMCs

with

the

expected

electrophysiological and pharmacological characteristics of Kv7 currents. The Gq/11coupled bronchoconstrictor agonists were observed to suppress Kv7 currents, but
the currents could be restored by drugs that are selective Kv7 channel activators.
These results motivated us to explore the functional relevance of Kv7 channels in
further detail using ex vivo precision-cut lung slices (PCLS). Our initial PCLS studies
revealed

that

Kv7

channel

activators
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are

capable

of

attenuating
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bronchoconstrictor agonist induced airway constriction, highlighting an important
contribution of these channels in maintaining the airway diameter. These findings
also provide the first evidence in support of our key hypothesis that Kv7 channels
have an important role to play in the pathophysiology of AHR. A series of studies
were then performed comparing the expression of Kv7 channel subtypes in
asthmatic airways to normal airways using a suitable model of asthma and
examining the modulation of Kv7 channel function in diseased airways. Some of the
key findings from our studies and their implications for our current understanding
of AHR are discussed below.
Kv7 channels in ASMCs
Our findings reported in this thesis indicate that Kv7 channels are expressed
in ASMCs. Multiple Kv7 channel subtypes were found to be expressed in both guinea
pig and human ASMCs, although their expression pattern differed in the two species.
Guinea pig ASMCs expressed KCNQ2>KCNQ5>KCNQ4>KCNQ3>>KCNQ1, while
human ASMCs expressed KCNQ1>KCNQ4>KCNQ5>KCNQ3. The expression pattern
in human ASMCs was similar to that reported in vascular smooth muscle cells
(VSMCs) in mouse and rat arteries (expression of KCNQ1, KCNQ4, and KCNQ5, with
little or no detectable KCNQ2 or KCNQ3) (Brueggemann et al. 2012; Joshi et al.
2009; Yeung et al. 2007). In human arteries, only KCNQ2 was undetectable (Ng et al.
2011). The expression pattern for KCNQ1 and KCNQ2 mRNAs was different
between normal guinea pig and human ASMCs. KCNQ2 was the most abundant
KCNQ transcript in guinea pig ASMCs, but was undetectable in human ASMCs,
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whereas KCNQ1 was most abundant in human and barely detectable in guinea pig.
The reason for these inter-species differences in Kv7 channel expression pattern
and their functional impact on airway function still remains to be determined. The
results from the expression studies were confirmed using immunofluorescence
detection of Kv7 channel proteins in normal guinea pig and human ASMCs. These
studies also indicated the presence of multiple Kv7 channel subtypes in both human
and guinea pig ASMCs, but with similar expression patterns between the species.
However, this method is not quantitative and the findings are highly dependent on
the quality of available antibodies. Therefore, caution should be exercised while
interpreting the immunofluorescence data.
While evaluating the findings from electrophysiological studies (as discussed
in Chapter 1) in context with the expression studies (as presented in Chapter 4), it is
important to take into consideration that any of the expressed Kv7 channel protein
subtypes can potentially contribute to the K+ currents measured in guinea pig or
human ASMCs. Therefore, robust currents were detected in guinea pig ASMCs where
KCNQ1 expression was not detected. Selective activators of Kv7.2–7.5 subtypes,
flupirtine and retigabine, robustly enhanced the currents in both guinea pig and
human ASMCs. Combined together, the data indicates that there is a likelihood of
some combination of Kv7.2–7.5 subtypes forming functional channels in both guinea
pig and human ASMCs that contribute to the regulation of airway diameter.
When we extended the expression studies to allergen-sensitized airways
obtained from a guinea pig model of AHR, our preliminary results (n=4) showed a
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trend indicating a decrease in the expression of all KCNQ isoforms in allergensensitized guinea pig airways compared to the saline-controls. We plan to repeat
these experiments to increase the sample size. However, conclusions from these
data will be drawn with caution as reduced expression of genes does not necessarily
mean reduced presence of functional protein products, hence confirming the
decrease in translational gene product would further strengthen our conclusions
from the expression studies. If the expression of KCNQ genes is consistently found to
be low, then this observation will have important implications on our understanding
of the etiology of AHR. It will suggest to us that AHR in asthma is likely to be caused
by bronchoconstrictor agonist-mediated suppression of genes encoding Kv7
channel. This will initiate efforts on our part to investigate the effectors downstream
of Gq/11 coupled receptors that are responsible for reduction in KCNQ mRNA levels
in allergen-sensitized airways. The mRNA levels in cells can be regulated at the
transcriptional and post-transcriptional stages (Latchman 2005). A number of
mechanisms can potentially be involved in regulating mRNA levels at these stages.
For example, the transcriptional regulation can result from alteration of various
transcriptional factors, while the post-transcriptional regulation can be effected by
modulation of capping, splicing or poly(A) tail addition processes. Therefore, it will
be interesting to investigate the exact mechanism leading to decrease in KCNQ
mRNA levels in allergen-sensitized guinea pig airways. Additionally, if the functional
Kv7 channel protein level is found to be unaffected in allergen-sensitized guinea pig
ASMCs, we will continue to perform experiments to investigate the mechanism of
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the suppressive effect of bronchoconstrictor agonists on Kv7 channel activity as
seen in the electrophysiological and PCLS studies (discussed in next section).
Kv7 channel activity in ASMCs and its significance in AHR
AHR, in simple terms, can be defined as airways that constrict “too easily”
and “too much” in response to particular stimuli. A number of pharmacological (eg.
bronchoconstrictor agonists), chemical (eg. allergens) and physical (eg. exercise)
stimuli can lead to such an exaggerated response. The diagnosis of asthma is
generally made when bronchoconstrictor agonists that act directly on ASMCs induce
constriction of airways at lower than normal concentrations, or when airways
constrict with a lower threshold of indirect bronchial provocation (e.g., exercise or
inhalation of cold air). In agreement with these well documented facts, our
bronchoconstrictor agonist dose-response studies using PCLS preparations showed
increased sensitivity to histamine and methacholine in allergen-sensitized guinea
pigs compared to the saline control. There was an approximate 4.5-fold decrease in
the EC50 value for histamine and ~2.5-fold decrease in the EC50 value for
methacholine in allergen-sensitized guinea pig airways compared to saline control.
Importantly, in addition to the increased airway sensitivity, there was a notable
increase in the Emax values in allergen-sensitized airways indicating a concomitant
increase in the magnitude of constriction. Thus the allergen-sensitized guinea pig
airways constricted “too easily” and “too much” in response to bronchoconstrictor
agonist, suggesting airway hyper-sensitization. The hyper-sensitization of airways
was also confirmed by application of ovalbumin (chemical stimulus) to the allergen-
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sensitized PCLS preparation. Passive challenge with 1 µg/ml of ovalbumin
completely constricted airways that were actively sensitized.
The underlying mechanism for increased sensitivity of airways to multiple
direct and indirect stimuli in asthma patients is one of the key questions that remain
unanswered. In line with our working hypothesis, a possible mechanism for
sensitization of ASMCs to multiple bronchoconstrictor stimuli could be a reduction
in K+ channel activity associated with an increase in electrical resistance of ASMC
plasma membrane. According to Ohm’s law, voltage is proportional to the product of
current and resistance. Therefore, an increase in resistance would enable a small
current to produce a larger change in voltage. In other words, a reduction in
outward K+ currents would increase membrane resistance and thereby serve to
sensitize ASMCs to depolarizing stimuli (depolarizing stimuli include small
increases in inward current, e.g., due to activation of Cl- or cation channels in
response to bronchial provocation). Thus bronchial provocation would tend to
induce greater membrane depolarization and activation of voltage-sensitive calcium
channels (VSCC) when K+ channel activity is reduced. Such a mechanism is
consistent with the observation that the sensitivity of porcine trachealis muscle to
histamine-induced contraction was enhanced in the presence of a nonspecific K+
channel blocker (tetraethylammonium, 10 mM), and that this effect was abolished
by the calcium channel blocker verapamil (Mitchell et al. 1987). If Kv7 channel
activity in ASMCs were reduced in asthma, bronchial provocation by
pharmacological or mechanical stimulation would more effectively depolarize the
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cells to activate L-type VSCC and enhance airway constriction. Our preliminary
results from Kv7 channel expression studies in allergen-sensitized airways indeed
suggest a decrease in Kv7 channel expression level that may lead to reduced Kv7
channel activity. Conversely, increasing Kv7 channel activity would reduce ASMC
electrical excitability and decrease the sensitivity to bronchial provocation. In
agreement with this hypothesis, our PCLS studies in normal guinea pigs indicate a
dose-dependent constriction of airways with histamine and attenuation of this
response in the presence of Kv7 channel activator, retigabine. Similarly, despite
their reduced expression in allergen-sensitized airways, we believe that an increase
in the activity of the remaining Kv7 channels is likely to decrease the sensitivity of
allergen-sensitized airways to bronchial provocation. In our investigation of this
effect we observed a dose-dependent constriction of allergen-sensitized airways
with histamine and significant attenuation of this response in the presence of Kv7
channel activator, retigabine. Therefore, these results provide us an insight in to
how Kv7 channel expression and function in airways play a role in regulation of
airway diameter. Importantly, the attenuation of bronchoconstrictor agoinstmediated airway constriction by Kv7 channel activators in allergen-sensitized
airways indicates promising application of Kv7 channel activators in treatment of
airway hyperresponsiveness.
Pharmacological targeting of Kv7 channels in ASMCs
Bronchoconstrictor agonists depolarize ASMC membrane potentials positive
to the L-type VSCC activation threshold which is likely to activate L-type VSCC
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leading to influx of

Ca+2

and bronchoconstriction (Hirota et al. 2007). Therefore, an

effective way of antagonizing agonist induced bronchoconstrictor effect is to block
L-type VSCC. As discussed in chapter 1, a number of clinical trials were conducted in
the early 1980’s to evaluate the efficacy of L-type Ca2+ channel blockers (CCBs) in
the treatment of asthma. The results were inconsistent, although almost all the
clinical trials revealed at least a subset of patients who benefited from treatment
with either verapamil or nifedipine (Fish et al. 1984). Taken as a whole, the clinical
trials revealed that asthma patients benefit from treatment with CCBs, but the
efficacy of these agents is limited because of adverse side effects associated with
systemic administration and limitations of formulation that prevent delivery of
effective doses of verapamil or nifedipine by inhalation (Fish et al. 1984). Our
ongoing studies have indicated that the bronchoconstrictor effect of histamine at
lower concentration (≤ 1 μM) is effectively attenuated by CCBs like verapamil.
However, verapamil is not effective in attenuating the effect of histamine used in
higher concentrations (10 μM), thus indicating that at high agonist concentration,
the bronchoconstrictor effect of histamine is independent of L-type VSCC. This is in
agreement with the previously published study from our laboratory, showing
concentration dependent signaling of Gq/11 receptor agonist vasopressin (AVP) in
vascular smooth muscle cells (VSMCs) (Henderson et al. 2007). The local
concentration of histamine in normal and allergen-sensitized airways is not known
but given the fact that CCBs show significant protection against bronchoconstriction
induced by exogenously administered histamine in human subjects (Cuss et al.
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1985). It remains to be determined whether the local histamine concentration in
asthmatic airways is in the range where CCBs are effective.
The Kv7 channel activators, by means of their membrane repolarizing
property, can ultimately have the same effect of reducing Ca2+ influx in ASMCs as
with CCBs therapy.

Although our studies suggest reduced expression of Kv7

channels in allergen-sensitized airways, it was also observed that Kv7 channel
activator, retigabine, can attenuate the bronchoconstrictor agonist-mediated
constriction, possibly by enhancing the activity of the remaining Kv7 channels. In
general, Kv7 channel activators have well-established clinical safety profiles when
administered systemically, and it may also be possible to develop inhalational
formulations of these drugs, which would reduce off-target effects. Furthermore, if
the Kv7 channel subunit stoichiometry in ASMCs differs from that of channels found
in other tissues, it may be possible to develop drugs that have selectivity for ASMC
Kv7 channels further improving their safety profile.
If we reproducibly measure decreased level of KCNQ mRNA in allergensensitized guinea pig airways, we will focus our efforts in identifying transcriptional
or post-transcriptional events that lead to reduced KCNQ mRNA levels. Depending
on the mechanism responsible for reduced expression, gene therapy would be a
viable therapeutic approach. Gene therapy has shown tremendous potential in the
treatment of disease like cystic fibrosis by replacement of mutated Cystic Fibrosis
Transmembrane Regulator (CFTR) gene (Corbyn 2012). Gene thearpy is a promising
approach as it targets the cause of a disease rather than just controlling the
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symptoms. However, the success of this approach would depend on the mechanism
that is responsible for reduced mRNA levels in allergen-sensitized airways.
Summary
In summary, our results reveal a novel and fundamental mechanism for regulating
airway diameter. Our studies demonstrate that the activity of Kv7 potassium
channels in ASMCs under resting conditions is essential to maintain the relaxed
state of the airways. Preliminary findings suggest that bronchial provocation of
airways with a known allergen reduces the expression of Kv7 channels. Ultimately,
this may lead to potentiation of the bronchoconstrictor effects mediated by
bronchoconstrictor agonists, and thereby account for airway hypersensitization.
Our results also provide evidence that despite the reduced expression of Kv7
channel in diseased airways, Kv7 channel activators are still effective in attenuating
the bronchoconstrictor effect of a bronchoconstrictor agoinst, indicating that these
drugs may be useful in the treatment of airway hyperconstriction in asthma or other
airway diseases. After confirming that there is a proportionate decrease in the
functional Kv7 channel protein as a result of reduced KCNQ genes expression, it will
be interesting to investigate the underlying mechanisms of the decreased Kv7
channel expression upon bronchial provocation.
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